|
|
Si bone inc (NASDAQ: SIBN) |
|
Price: $16.6900
$-0.23 
-1.359%
|
| Day's High:
| $17.23
| Week Perf:
| 2.83 %
|
| Day's Low: |
$ 16.67 |
30 Day Perf: |
21.21 % |
| Volume (M): |
294 |
52 Wk High: |
$ 21.64 |
| Volume (M$): |
$ 4,914 |
52 Wk Avg: |
$15.17 |
| Open: |
$17.23 |
52 Wk Low: |
$11.70 |
|
|
| Market Capitalization (Millions $) |
696 |
| Shares
Outstanding (Millions) |
42 |
| Employees |
370 |
| Revenues (TTM) (Millions $) |
156 |
| Net Income (TTM) (Millions $) |
-37 |
| Cash Flow (TTM) (Millions $) |
-23 |
| Capital Exp. (TTM) (Millions $) |
9 |
Si Bone Inc
Si-Bone Inc. is a medical device company that focuses on the development and distribution of minimally invasive surgical devices for the treatment of musculoskeletal disorders. The company was founded in 2008 and is based in Santa Clara, California.
One of Si-Bone's most groundbreaking products is the iFuse Implant System, which is used to treat sacroiliac joint dysfunction. This condition is often caused by damage or degeneration to the sacroiliac joint, which can result in severe lower back pain and negatively impact a patient's quality of life.
The iFuse Implant System consists of a set of triangular shaped implants that are surgically placed across the sacroiliac joint, providing support to the affected area while promoting fusion of the joint. This technology has been proven effective in numerous clinical studies and has been used in thousands of surgical procedures.
In addition to their flagship product, Si-Bone also offers a range of other surgical devices for the treatment of musculoskeletal conditions. These include the iFuse-3D Implant System, which uses three-dimensional printing technology to create custom implants for patients, and the iFuse-CG Implant System, which provides additional compression and stability to the sacroiliac joint.
Si-Bone is known for its commitment to innovation, with a team of talented engineers and researchers constantly working to develop and improve their surgical technologies. The company has also established strong partnerships with leading medical institutions, including the Mayo Clinic and Harvard Medical School.
Si-Bone's products have been widely adopted by healthcare professionals, and the company has received numerous industry accolades for its innovative technologies. They continue to expand their presence in the medical device industry, with a focus on improving patient outcomes and providing minimally invasive solutions for a wide range of musculoskeletal conditions.
Company Address: 471 El Camino Real Santa Clara 95050 CA
Company Phone Number: 207-0700 Stock Exchange / Ticker: NASDAQ SIBN
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Product Service News
Published Tue, Nov 5 2024 1:30 PM UTC
In the competitive landscape of medical devices, companies are continually grappling with regulatory hurdles and market dynamics that can significantly impact their growth trajectories. Among those navigating this challenging terrain is SI-BONE, a company specializing in surgical implants for the treatment of the sacroiliac joint and other orthopedic applications. Recently, ...
|
| Product Service News
Published Thu, Oct 10 2024 12:30 PM UTC
In a groundbreaking development for the medical device industry and the treatment of pelvic fractures, SI-BONE, Inc., a leading innovator in surgical solutions for sacropelvic disorders, has successfully completed the first-in-patient procedures utilizing its FDA-designated breakthrough device, the iFuse TORQ TNT Implant System. Announced on October 10, 2024, the significant...
|
| Management Announcement
Published Tue, Aug 20 2024 12:30 PM UTC
SANTA CLARA, Calif., Aug. 20, 2024 - SI-BONE, Inc. (Nasdaq: SIBN), a leading medical device company specializing in surgical solutions for sacropelvic disorders, has recently obtained FDA 510(k) clearance for its innovative iFuse TORQ TNT Implant System (TNT). This breakthrough technology is specifically designed to address the anatomical and bone mineral density ...
|
| Si Bone Inc
Si Bone Inc., a renowned medical device company specialized in musculoskeletal disorders of the sacropelvic anatomy, has recently achieved FDA 510(k) clearance for its enhanced iFuse Bedrock Granite Implant System. This advanced system boasts a smaller diameter of 9.5 mm, rendering it more adaptable for usage in diverse anatomical conditions. Moreover, the clearance now encompasses an expanded indication for pediatric patients, as well as an extended application that encompasses the S1 trajectory.
The iFuse Bedrock Granite Implant System is designed to facilitate sacroiliac (SI) joint fusion and sacropelvic fixation when positioned across the SI joint. This implant assumes a foundational role in multi-segment spinal fusion, thereby offering more holistic solutions for individuals afflicted with musculoskeletal disorders. The expanded indication for pediatric patients is a significant development, as it represents a breakthrough for younger individuals who previously had limited treatment options for this condition.
|
| Si Bone Inc
SI-BONE, Inc., a leading medical device company specializing in musculoskeletal disorders of the sacropelvic anatomy, has recently announced its financial results for the fourth quarter and full year ended December 31, 2023. The company reported an improvement in its earnings per share (EPS) compared to the previous year, with a decrease in loss per share from $-0.31 to $-0.24. Additionally, the company saw a sequential improvement in EPS from $-0.25 in the preceding financial reporting period.
One of the highlights of SI-BONE's financial performance was the significant increase in revenue. The company experienced a rapid revenue growth of 21.278%, with revenues reaching $38.75 million in the fourth quarter of 2023 compared to $31.95 million in the same period a year ago. Furthermore, the company's revenue also increased by 14.067% sequentially from $33.97 million.
|
| Per Share |
Current |
| Earnings (TTM) |
-0.89 $ |
| Revenues (TTM) |
3.74 $
|
| Cash Flow (TTM) |
- |
| Cash |
0.72 $
|
| Book Value |
3.95 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-0.89 $
|
| Revenues (TTM) |
3.74 $ |
| Cash Flow (TTM) |
- |
| Cash |
0.72 $
|
| Book Value |
3.95 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| United States |
|
 95.89 % |
of total Revenue |
| International |
|
5.21 % |
of total Revenue |
| |
On August 5 2024 the Si Bone Inc provided following guidance
nnSI-BONE, Inc. Financial Performance Update for the Second Quarter of 2024nn
SI-BONE, Inc. has announced its financial outcomes for the second quarter of 2024, along with an optimistic update on its revenue expectations for the year. The company has raised its revenue forecast for 2024, now anticipating that total revenues will be between $165 million and $167 million. This upward revision reflects confidence in the company's growth trajectory and market demand for its products.
Moreover, SI-BONE is projecting a significant milestone, stating that it expects to achieve positive Adjusted EBITDA in the fourth quarter of 2024. This marks a notable point in the company's financial strategy as it a...
|
|
|
2.82% 